We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Biochemical Abnormalities Among Celiac Disease Patients Referred for Antibody Testing

By LabMedica International staff writers
Posted on 09 May 2022

Celiac disease (CD) is a chronic disease occurring in all age groups and affecting approximately 1% of the population, although many cases of CD remain undiagnosed. More...

This condition is caused by an abnormal immune response in genetically susceptible individuals triggered by the ingestion of gluten proteins from wheat, rye and barley.

Celiac disease primarily affects the small intestine, often leading to malabsorption and micronutrient deficiencies. A small intestinal biopsy with recognition of villus atrophy and inflammation has been the gold standard for diagnosis; however, serological testing is increasingly used in the diagnostic process and screening for CD, mainly by the detection of CD-specific antibodies.

Clinical Scientists at the Copenhagen University Hospital (Copenhagen, Denmark) and their colleagues included in an observational cohort study 706 individuals that had received a positive CD antibody result; 72.7% were women and the mean age was 26 years. The team compared the results of those with CD-positive antibodies with individuals with CD-negative antibodies.

Tissue transglutaminase antibody (IgA) (TTG-IgA), tissue transglutaminase antibody (IgG) (TTG-IgG), deamidated gliadin peptide antibody (IgA) (DGP-IgA) and deamidated gliadin peptide antibody (IgG) (DGP-IgG) were measured in serum by fluorescence enzyme immunoassay (EIA) on the UniCAP 100 and ImmunoCAP 250 platforms (Phadia Laboratory Systems, Thermo Fisher Scientific, Hvidovre, Denmark).

Other variables used from the CopLab database were hemoglobin, erythrocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), transferrin, hematocrit, ferritin, alanine transaminase (ALAT), alkaline phosphate, 25-OH vitamin D, folic acid, cobalamin, C-reactive protein (CRP), reticulocyte, mean corpuscular hemoglobin (ReticMCH), erythrocyte volume, relative distribution width (RDW), and immunoglobulin A.

The investigators reported a most remarkable difference between the groups was the markedly lower ferritin among CD antibody-positive individuals compared with CD antibody-negative individuals (women: 13.8 µg/L versus. 35.9 µg/L; men: 34.3 µg/L versus 80.4 µg/L), Also, CD antibody-positive individuals had a tendency for lower hemoglobin (women: 7.8 mmol/L versus 8.1 mmol/L; men: 8.5 mmol/L versus 8.8 mmol/L). The team reported lower cobalamin and folic acid levels and higher levels of transferrin, alanine transaminase and alkaline phosphate among CD antibody-positive individuals.

Compared with CD-negative individuals, the scientists reported that a greater proportion of tests among CD antibody-positive individuals exhibited hemoglobin (10.2% versus 2.7%), mean corpuscular volume (7.1% versus 2.9%), mean corpuscular hemoglobin concentration (6.8% versus 1.2%) and ferritin (37.6% versus7.6%) below the reference level, while transferrin (20.7% versus 9.5%) was above the reference interval. CD antibody-positive individuals were also more likely to have a deficiency for cobalamin and folic acid.

Line Lund Kårhus, MD, PhD, the lead author of the study, said, “This study identified several biochemical abnormalities associated with celiac disease (CD) antibody positivity in a primary care setting among individuals referred to CD antibody testing. The pattern of abnormalities suggested that micronutrient deficiencies were prevalent among CD antibody-positive individuals.”

The authors concluded that their study showed more measurements below the reference interval for hemoglobin, MCV, MCHC, ferritin, cobalamin and folic acid among the individuals with a positive CD antibody test. The pattern of the included biomarkers suggested that micronutrient deficiencies were common among CD antibody-positive individuals and confirmed malabsorption as a sign of CD. The study was published on April 18, 2022 in the journal Scientific Reports.

Related Links:
Copenhagen University Hospital 
Phadia Laboratory Systems 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.